search
Back to results

Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis (CATCH-IT)

Primary Purpose

Primary Sclerosing Cholangitis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Liver Multiscan sequences
Liver Multiscan analysis
MRCP+
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Primary Sclerosing Cholangitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Established PSC diagnosis according to the IPSCSG definitions
  • Age ≥ 18
  • Able to give informed consent

Exclusion Criteria:

  • Post LTx
  • Known allergy for MRI contrast agents, implants non-compatible with MRI or extreme claustrophobia causing discontinuation of MRI studies.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    Additional sequences with MRCP+ and LiverMultiscan

    Arm Description

    PSC patients that undergo annual, standard care, MRI of the liver and MRCP will undergo additional Liver Multiscan sequences, taking approximately 15 minutes. After the MRI is performed, post-processing analysis named MRCP+ and LiverMultiscan will be performed without patient involvement.

    Outcomes

    Primary Outcome Measures

    Delta of cT1 in patients with PSC during follow-up
    The delta of cT1 (in ms), measured by LiverMultiscan, which will be assessed by performing paired t-tests.

    Secondary Outcome Measures

    Assesment of th mean, median and range of cT1 and MRCP+ metrics in stable PSC patients
    Mean, median and range of cT1 and MRCP+ metrics in clinically and biochemically stable patients with PSC during the period of 1 year to establish general statistics as these are unknown at current writing
    Variance of the delta of cT1 and MRCP+ metrics in stable patients
    Variance of the delta in cT1 and MRCP+ metrics from baseline to year 1 in clinically and biochemically stable patients
    Difference in cT1 in patients with or without endoscopic intervention
    Difference in mean of cT1 values in patients who needed ERCP with treatment of dominant stricture(s) in the year following LMS measurement versus those who did not need an intervention
    Variance in unstable patients
    Variance of the delta of cT1 and MRCP+ metrics in sequential scans in biochemically and/or clinically deteriorating patients.
    Correlation of cT1 and MRCP+ metrics with fibroscan and MELD
    Correlation between cT1 and MRCP+ metrics with Fibroscan and MELD-score
    Correlation of cT1 and MRCP+ metrics and development of dominant strictures
    Correlation between cT1 and MRCP+ metrics and development of dominant strictures
    Correlation of cT1 and MRCP+ metrics and incidence of CCA
    Correlation between cT1 and MRCP+ metrics and incidence of CCA

    Full Information

    First Posted
    June 17, 2022
    Last Updated
    July 13, 2022
    Sponsor
    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    Collaborators
    Perspectum
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05462093
    Brief Title
    Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis
    Acronym
    CATCH-IT
    Official Title
    Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis: the CATCH-IT Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 2022 (Anticipated)
    Primary Completion Date
    July 2028 (Anticipated)
    Study Completion Date
    July 2029 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    Collaborators
    Perspectum

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Primary sclerosing cholangitis (PSC) is a chronic progressive biliary disease that affects approximately 1200 patients in the Netherlands and around 80,000 in the Western world. It is often accompanied by ulcerative colitis (UC) or Crohn's disease affecting the large bowel. The cause of PSC is unknown, there is no medical therapy available that has proven to halt disease progression and the median time until death or liver transplantation is 13-21 years. Diagnosis is made by magnetic resonance cholangiography (MRC), or in the case of so called small duct disease by liver biopsy. Due to the heterogeneous disease course and the relatively low clinical event rate of 5% per year it is difficult to predict prognosis of individual patients or to recommend any surveillance strategy for malignancies. Also, the lack of surrogate endpoints impedes performing clinical research. Recently, two new post-processing tools have been developed to characterize and quantify abnormalities in the biliary tree as well as excretory function captured by MRC. These tools called MRCP+ (quantitative magnetic resonance cholangiopancreatography +) and LiverMultiscan (LMS) hold the prospect of adequately depicting and quantifying lesions of the biliary tree as well as capturing functional derailment. However, several features must be tested before the utility of this tools in clinical patient care can be concluded. Therefore, the aim of this study is to investigate the utility of these novel techniques in monitoring disease activity by performing consecutive annual MRI's.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Primary Sclerosing Cholangitis

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    200 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Additional sequences with MRCP+ and LiverMultiscan
    Arm Type
    Other
    Arm Description
    PSC patients that undergo annual, standard care, MRI of the liver and MRCP will undergo additional Liver Multiscan sequences, taking approximately 15 minutes. After the MRI is performed, post-processing analysis named MRCP+ and LiverMultiscan will be performed without patient involvement.
    Intervention Type
    Device
    Intervention Name(s)
    Liver Multiscan sequences
    Intervention Description
    Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
    Intervention Type
    Device
    Intervention Name(s)
    Liver Multiscan analysis
    Other Intervention Name(s)
    LMS
    Intervention Description
    Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
    Intervention Type
    Device
    Intervention Name(s)
    MRCP+
    Intervention Description
    Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
    Primary Outcome Measure Information:
    Title
    Delta of cT1 in patients with PSC during follow-up
    Description
    The delta of cT1 (in ms), measured by LiverMultiscan, which will be assessed by performing paired t-tests.
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52; 3rd MRI = year 2 = week 104; 4th MRI = year 3 = week 156; 5th MRI = year 4 = week 208; 6th MRI = year 5 = week 260.
    Secondary Outcome Measure Information:
    Title
    Assesment of th mean, median and range of cT1 and MRCP+ metrics in stable PSC patients
    Description
    Mean, median and range of cT1 and MRCP+ metrics in clinically and biochemically stable patients with PSC during the period of 1 year to establish general statistics as these are unknown at current writing
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52;
    Title
    Variance of the delta of cT1 and MRCP+ metrics in stable patients
    Description
    Variance of the delta in cT1 and MRCP+ metrics from baseline to year 1 in clinically and biochemically stable patients
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52; 3rd MRI = year 2 = week 104; 4th MRI = year 3 = week 156; 5th MRI = year 4 = week 208; 6th MRI = year 5 = week 260.
    Title
    Difference in cT1 in patients with or without endoscopic intervention
    Description
    Difference in mean of cT1 values in patients who needed ERCP with treatment of dominant stricture(s) in the year following LMS measurement versus those who did not need an intervention
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52; 3rd MRI = year 2 = week 104; 4th MRI = year 3 = week 156; 5th MRI = year 4 = week 208; 6th MRI = year 5 = week 260.
    Title
    Variance in unstable patients
    Description
    Variance of the delta of cT1 and MRCP+ metrics in sequential scans in biochemically and/or clinically deteriorating patients.
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52; 3rd MRI = year 2 = week 104; 4th MRI = year 3 = week 156; 5th MRI = year 4 = week 208; 6th MRI = year 5 = week 260.
    Title
    Correlation of cT1 and MRCP+ metrics with fibroscan and MELD
    Description
    Correlation between cT1 and MRCP+ metrics with Fibroscan and MELD-score
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52; 3rd MRI = year 2 = week 104; 4th MRI = year 3 = week 156; 5th MRI = year 4 = week 208; 6th MRI = year 5 = week 260.
    Title
    Correlation of cT1 and MRCP+ metrics and development of dominant strictures
    Description
    Correlation between cT1 and MRCP+ metrics and development of dominant strictures
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52; 3rd MRI = year 2 = week 104; 4th MRI = year 3 = week 156; 5th MRI = year 4 = week 208; 6th MRI = year 5 = week 260.
    Title
    Correlation of cT1 and MRCP+ metrics and incidence of CCA
    Description
    Correlation between cT1 and MRCP+ metrics and incidence of CCA
    Time Frame
    1st MRI = baseline = week 0; 2nd MRI = year 1 = week 52; 3rd MRI = year 2 = week 104; 4th MRI = year 3 = week 156; 5th MRI = year 4 = week 208; 6th MRI = year 5 = week 260.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Established PSC diagnosis according to the IPSCSG definitions Age ≥ 18 Able to give informed consent Exclusion Criteria: Post LTx Known allergy for MRI contrast agents, implants non-compatible with MRI or extreme claustrophobia causing discontinuation of MRI studies.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Tim E Middelburg, MSC
    Phone
    +31648510414
    Email
    t.e.middelburg@amsterdamumc.nl
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Cyriel Ponsioen, Prof MD PhD
    Organizational Affiliation
    Gastroenterologist and hepatologist
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    After publication, the following documentation can be requested by qualified research groups: - Study protocol, statistical analysis plan and the clinical study report can be provided if a proper request is submitted. IPD will contain decoded and only essential data for the objective of this study. Data that will be available for sharing purposes will only include decoded demographic data. Furthermore, MRCP+ data that underlies the results in the publication will be available for sharing, e.g. MRCP+ metrics
    IPD Sharing Time Frame
    Until 5 years after publication
    IPD Sharing Access Criteria
    Data sharing can be requested by qualified research groups. Requests will be evaluated by the following method: The request is supposed to contain a clear objective and methodology. E.g., it must contain the objective to explore or validate the value of MRCP+ and LMS techniques. Furthermore, the study proposal could, for example, be a systematic review or meta-analysis. The request will be reviewed by a dedicated research team of the CATCH-IT-study. This research team contains the PI, PhD student, involved gastro-enterologist and radiologist and representative of Perspectum Ltd. If the request seems valid and the credibility of the requesting party is validated, data sharing agreement will be developed with the local research support team. To submit a request, contact t.e.middelburg@amsterdamumc.nl
    Citations:
    PubMed Identifier
    27653566
    Citation
    Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med. 2016 Sep 22;375(12):1161-70. doi: 10.1056/NEJMra1506330. No abstract available.
    Results Reference
    background
    PubMed Identifier
    26938805
    Citation
    Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol. 2016 Apr;28(4):383-90. doi: 10.1097/MEG.0000000000000576.
    Results Reference
    background
    PubMed Identifier
    31902255
    Citation
    Barner-Rasmussen N, Pukkala E, Jussila A, Farkkila M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol. 2020 Jan;55(1):74-81. doi: 10.1080/00365521.2019.1707277. Epub 2020 Jan 4.
    Results Reference
    background
    PubMed Identifier
    23775876
    Citation
    Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U, Ponsioen CY; EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013 Dec;58(6):2045-55. doi: 10.1002/hep.26565. Epub 2013 Oct 17.
    Results Reference
    background
    PubMed Identifier
    23810223
    Citation
    Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013 Nov 9;382(9904):1587-99. doi: 10.1016/S0140-6736(13)60096-3. Epub 2013 Jun 28.
    Results Reference
    background
    PubMed Identifier
    26418478
    Citation
    Ponsioen CY, Chapman RW, Chazouilleres O, Hirschfield GM, Karlsen TH, Lohse AW, Pinzani M, Schrumpf E, Trauner M, Gores GJ. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology. 2016 Apr;63(4):1357-67. doi: 10.1002/hep.28256. Epub 2015 Dec 23.
    Results Reference
    background
    PubMed Identifier
    20623444
    Citation
    Ponsioen CY, Reitsma JB, Boberg KM, Aabakken L, Rauws EA, Schrumpf E. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy. 2010 Sep;42(9):742-7. doi: 10.1055/s-0030-1255527. Epub 2010 Jul 9.
    Results Reference
    background
    PubMed Identifier
    25869391
    Citation
    Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015 May;110(5):646-59; quiz 660. doi: 10.1038/ajg.2015.112. Epub 2015 Apr 14.
    Results Reference
    background
    PubMed Identifier
    19501929
    Citation
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6. No abstract available.
    Results Reference
    background
    PubMed Identifier
    16616358
    Citation
    Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2006 Apr;4(4):514-20. doi: 10.1016/j.cgh.2005.10.007.
    Results Reference
    background
    PubMed Identifier
    20656832
    Citation
    Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010 Aug;256(2):387-96. doi: 10.1148/radiol.10091953.
    Results Reference
    background
    PubMed Identifier
    20101749
    Citation
    Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010 Feb;51(2):660-78. doi: 10.1002/hep.23294. No abstract available.
    Results Reference
    background
    PubMed Identifier
    27342213
    Citation
    Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, Viktil E, Henriksen M, Hovde O, Huppertz-Hauss G, Hoie O, Hoivik ML, Monstad I, Solberg IC, Jahnsen J, Karlsen TH, Moum B, Vatn M, Negard A. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology. 2016 Oct;151(4):660-669.e4. doi: 10.1053/j.gastro.2016.06.021. Epub 2016 Jun 21.
    Results Reference
    background
    PubMed Identifier
    31041791
    Citation
    Zenouzi R, Welle CL, Venkatesh SK, Schramm C, Eaton JE. Magnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions. Semin Liver Dis. 2019 Jul;39(3):369-380. doi: 10.1055/s-0039-1687853. Epub 2019 Apr 30.
    Results Reference
    background
    PubMed Identifier
    32147892
    Citation
    Goldfinger MH, Ridgway GR, Ferreira C, Langford CR, Cheng L, Kazimianec A, Borghetto A, Wright TG, Woodward G, Hassanali N, Nicholls RC, Simpson H, Waddell T, Vikal S, Mavar M, Rymell S, Wigley I, Jacobs J, Kelly M, Banerjee R, Brady JM. Quantitative MRCP Imaging: Accuracy, Repeatability, Reproducibility, and Cohort-Derived Normative Ranges. J Magn Reson Imaging. 2020 Sep;52(3):807-820. doi: 10.1002/jmri.27113. Epub 2020 Mar 8.
    Results Reference
    background
    PubMed Identifier
    27448630
    Citation
    Tunnicliffe EM, Banerjee R, Pavlides M, Neubauer S, Robson MD. A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1 (shMOLLI-T1 ) in the liver. J Magn Reson Imaging. 2017 Feb;45(2):450-462. doi: 10.1002/jmri.25392. Epub 2016 Jul 23.
    Results Reference
    background
    PubMed Identifier
    24036007
    Citation
    Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014 Jan;60(1):69-77. doi: 10.1016/j.jhep.2013.09.002. Epub 2013 Sep 12.
    Results Reference
    background
    PubMed Identifier
    27778429
    Citation
    Pavlides M, Banerjee R, Tunnicliffe EM, Kelly C, Collier J, Wang LM, Fleming KA, Cobbold JF, Robson MD, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int. 2017 Jul;37(7):1065-1073. doi: 10.1111/liv.13284. Epub 2017 May 30.
    Results Reference
    background
    PubMed Identifier
    30970039
    Citation
    Bachtiar V, Kelly MD, Wilman HR, Jacobs J, Newbould R, Kelly CJ, Gyngell ML, Groves KE, McKay A, Herlihy AH, Fernandes CC, Halberstadt M, Maguire M, Jayaratne N, Linden S, Neubauer S, Banerjee R. Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS One. 2019 Apr 10;14(4):e0214921. doi: 10.1371/journal.pone.0214921. eCollection 2019.
    Results Reference
    background
    PubMed Identifier
    26471505
    Citation
    Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016 Feb;64(2):308-315. doi: 10.1016/j.jhep.2015.10.009. Epub 2015 Nov 10.
    Results Reference
    background
    PubMed Identifier
    29886155
    Citation
    Bradley CR, Cox EF, Scott RA, James MW, Kaye P, Aithal GP, Francis ST, Guha IN. Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. J Hepatol. 2018 Nov;69(5):1015-1024. doi: 10.1016/j.jhep.2018.05.037. Epub 2018 Jun 8.
    Results Reference
    background
    Citation
    Selvaraj EA, Culver EL, Collier J, Ridgway GR, Brady JM, Bailey A, et al. Combination of quantitative MRCP and MRI demonstrates increased periductal iron-corrected T1 in primary sclerosing cholangitis. Gut. 2021;70(Suppl 1):A155.
    Results Reference
    background
    PubMed Identifier
    33671768
    Citation
    Okada F, Izutsu R, Goto K, Osaki M. Inflammation-Related Carcinogenesis: Lessons from Animal Models to Clinical Aspects. Cancers (Basel). 2021 Feb 22;13(4):921. doi: 10.3390/cancers13040921.
    Results Reference
    background
    PubMed Identifier
    23827861
    Citation
    Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1.
    Results Reference
    background
    PubMed Identifier
    34384749
    Citation
    Ponsioen CY, Assis DN, Boberg KM, Bowlus CL, Deneau M, Thorburn D, Aabakken L, Farkkila M, Petersen B, Rupp C, Hubscher SG; PSC Study Group. Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology. 2021 Dec;161(6):1764-1775.e5. doi: 10.1053/j.gastro.2021.07.046. Epub 2021 Aug 10. No abstract available.
    Results Reference
    background
    PubMed Identifier
    27683581
    Citation
    Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018 Jun;27(6):1785-1805. doi: 10.1177/0962280216669183. Epub 2016 Sep 27.
    Results Reference
    background
    PubMed Identifier
    25524443
    Citation
    Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014 Dec 19;14:135. doi: 10.1186/1471-2288-14-135.
    Results Reference
    background
    PubMed Identifier
    29907829
    Citation
    McDonald N, Eddowes PJ, Hodson J, Semple SIK, Davies NP, Kelly CJ, Kin S, Phillips M, Herlihy AH, Kendall TJ, Brown RM, Neil DAH, Hubscher SG, Hirschfield GM, Fallowfield JA. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Sci Rep. 2018 Jun 15;8(1):9189. doi: 10.1038/s41598-018-27560-5.
    Results Reference
    background
    PubMed Identifier
    28555945
    Citation
    Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J; MRI working group of the IPSCSG. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology. 2017 Nov;66(5):1675-1688. doi: 10.1002/hep.29293. Epub 2017 Sep 29.
    Results Reference
    background

    Learn more about this trial

    Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis

    We'll reach out to this number within 24 hrs